HistoSonics has completed a new funding round, led by Reed Jobs' Yosemite and joined by undisclosed strategic investors, to further expand the clinical adoption of its Edison® histotripsy system for liver tumors globally. The company plans to accelerate the development of its non-invasive platform for additional solid tumor applications. Specific funding amounts and other financial metrics were not disclosed.